Veracyte, Inc. Earnings Recaps
Q1 2026
May 7, 2026
Shares surged 23.1% reflecting investor enthusiasm driven by stronger-than-expected volume growth in Decipher tests, advancing clinical catalysts, and improving profitability metrics.
Key takeaways
- Decipher test volume rose 24% year-over-year to approximately 28,000 tests in Q1, driven by expanded provider adoption and higher orders per physician.
- Growth was particularly strong in high-risk prostate cancer categories, with nearly 30% volume increase in advanced disease segments.
- Multiple late-stage clinical trials (including GUIDANCE and ENZAMET) advancing, supporting Decipher’s potential as a treatment decision biomarker.
- Adjusted EBITDA margin exceeded expectations, reflecting ongoing operational efficiency improvements.
- Upcoming product launches (Prosigna LDT and TrueMRD) represent important growth levers to extend the platform and address new clinical settings.
Q3 2025
Nov 5, 2025
Veracyte delivered robust financial performance in Q3 2025, achieving 14% revenue growth year-over-year and a record adjusted EBITDA margin of 30%. The company's strategic focus on core testing products continues to drive impressive volume growth.
Key takeaways
- Total revenue reached approximately $132 million, bolstered by 26% growth in Decipher and 13% growth in Afirma tests.
- Adjusted EBITDA margin improved by 650 basis points year-over-year, surpassing the previously set goal of 25%.
- Decipher's testing volume exceeded 26,700, marking the 14th consecutive quarter of over 25% year-over-year growth and demonstrating increased clinical utility for advanced disease management.
- Strong research backing with 240 publications on Decipher, continuing to establish its relevance in prostate cancer treatment and diagnostics.